Zhifei Biologicals makes new progress in two independently developed projects

Source: Global Network

Recently, Zhifei Biological has made significant progress in the innovative research and development of vaccines. Its wholly-owned subsidiary, Beijing Zhifei Green Bamboo, has initiated Phase I clinical research for the adsorbed acellular DTPa (component) combined vaccine for type B Haemophilus influenzae (hereinafter referred to as the “DTPa-Hib quadrivalent vaccine”). The independently developed adsorbed tetanus vaccine has also started Phase I/III clinical research. These two advancements mark a key step in the company’s technical layout in the fields of multivalent vaccines and emergency tetanus vaccines.

Image: Zhifei Biological Beijing Research and Production Base

The DTPa-Hib quadrivalent vaccine is conducting Phase I clinical trials in Guangxi. Pertussis, diphtheria, tetanus, and Hib infections have high incidence and mortality rates among infants and children, posing a serious threat to children’s health. The DTPa-Hib quadrivalent vaccine, developed independently by Zhifei Biological, employs a new generation of “component purification” technology, resulting in high purity of the antigen components, precise content, and good consistency between batches. It can effectively prevent the aforementioned four diseases, reduce the number of vaccinations required, and enhance compliance with vaccination schedules. This project will create a synergistic effect with the company’s ongoing multivalent vaccines, helping to solidify the core product matrix in the multivalent vaccine field. If successfully launched, it will provide an efficient and convenient preventive solution for public health.

The adsorbed tetanus vaccine has officially commenced Phase I/III clinical enrollment in Chongqing. Tetanus, as a serious acute infectious disease, can be effectively prevented through immunization, but the issue of non-neonatal tetanus remains severe in China. This vaccine from Zhifei Biological utilizes column chromatography to purify effective antigens, resulting in higher purity and better immunogenicity compared to traditional salt precipitation methods, meeting the post-exposure prevention needs of adults and high-risk groups. The advancement of this project fills the product gap in the post-exposure immunization management field within the DTP series product pipeline, and if successfully launched, it will create a complete protective loop from basic immunization for children to emergency prevention for adults and high-risk populations within the existing DTP vaccine series.

In recent years, Zhifei Biological has adhered to innovation-driven development, continuously increasing R&D investment and technical breakthroughs. Currently, it has laid out 34 preventive research pipelines, of which 25 are in the stages of application, clinical trials, and registration. The recent progress of these two self-developed projects in clinical trials not only reflects the company’s concentrated research strength but also represents a pragmatic action to implement the Healthy China strategy and safeguard public health.

A relevant person in charge at Zhifei Biological stated that the company will continue to uphold the mission of “preventing diseases before they occur and treating existing diseases, safeguarding human health,” continuously strengthening its technological transformation capabilities from laboratory R&D to market application, and using high-quality innovative achievements to support the construction of the disease prevention and control system.